Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 38 min ago
Peer-reviewedCC BY 4.0Leukemia

Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach

  • Raajit K. Rampal1,2
  • Richard Winneker3
  • Andrew Kuykendall4
  • Laura C. Michaelis5
  • Ghaith Abu-Zeinah6
  • Steffen Koschmieder7
  • Jan Philipp Bewersdorf8
  • Zi Yun Ng9
  • Gabriella Hobbs10
  • Bridget Marcellino11
  • Linda Resar12
  • Joseph Scandura6
7 more authors
  • Anand Patel13
  • John Mascarenhas11
  • Aaron Gerds14
  • Douglas Tremblay11
  • Shane Mayack2
  • Andriy Derkach1
  • Florian H. Heidel15
15 affiliations
  1. 1Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY USA
  2. 2Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY USA
  3. 3MPN Research Foundation, Chicago, IL USA
  4. 4Malignant Hematology Department, H Lee Moffitt Cancer Center, Tampa, FL USA
  5. 5Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI USA
  6. 6Weill Cornell Medical College, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY USA
  7. 7Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, University of Aachen, Aachen, Germany
  8. 8Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT USA
  9. 9Department of Haematology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
  10. 10Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA USA
  11. 11Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY USA
  12. 12Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD USA
  13. 13Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL USA
  14. 14Cleveland Clinic Taussig Cancer Institute, Cleveland, OH USA
  15. 15Hematology, Hemostasis, Oncology and Cell Therapy, Hannover Medical School (MHH), Hannover, Germany
Read full textPDFDOICite

Related

  1. Allele burden expansion in JAK2 V617F and CALR ‐mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment
    Zi Yun Ng, Laurane Cottin, Marine Demoy +16
    HemaSpherePeer-reviewedCC BY 4.0Full textHuman geneticsHAL
  2. The JAK2 V617F revolution in myeloproliferative neoplasms.
    Ayalew Tefferi
    HaematologicaPeer-reviewedCC BY-NCFull textHuman geneticsEurope PMCPMC
  3. FDX1 is associated with CALR abundance and JAK–STAT-related inflammatory signaling in myeloproliferative neoplasms
    Diyaer Abuduaini, Diernu Simayi, Mihelayi Maimaiti +2
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  4. Megakaryocytic proteomic signatures define myeloproliferative neoplasms
    I. Raman, C. Bennett, S.-R. Pasricha +12
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  5. Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
    Valérie Bardet, Wagner-Ballon O, Guy J +12
    HaematologicaPeer-reviewedLicence not statedFull text43 citedGeneral biologyGeneral medicineHAL

Cite

BibTeXRIS
BibTeX
@article{rampal2026defining,
  title = {{Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach}},
  author = {Raajit K. Rampal and Richard Winneker and Andrew Kuykendall and Laura C. Michaelis and Ghaith Abu-Zeinah and Steffen Koschmieder and Jan Philipp Bewersdorf and Zi Yun Ng and Gabriella Hobbs and Bridget Marcellino and Linda Resar and Joseph Scandura and Anand Patel and John Mascarenhas and Aaron Gerds and Douglas Tremblay and Shane Mayack and Andriy Derkach and Florian H. Heidel},
  journal = {Leukemia},
  year = {2026},
  month = sep,
  doi = {10.1038/s41375-026-03103-0},
  url = {https://doi.org/10.1038/s41375-026-03103-0},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach
AU  - Raajit K. Rampal
AU  - Richard Winneker
AU  - Andrew Kuykendall
AU  - Laura C. Michaelis
AU  - Ghaith Abu-Zeinah
AU  - Steffen Koschmieder
AU  - Jan Philipp Bewersdorf
AU  - Zi Yun Ng
AU  - Gabriella Hobbs
AU  - Bridget Marcellino
AU  - Linda Resar
AU  - Joseph Scandura
AU  - Anand Patel
AU  - John Mascarenhas
AU  - Aaron Gerds
AU  - Douglas Tremblay
AU  - Shane Mayack
AU  - Andriy Derkach
AU  - Florian H. Heidel
PY  - 2026
DA  - 2026/09/01
JO  - Leukemia
DO  - 10.1038/s41375-026-03103-0
UR  - https://doi.org/10.1038/s41375-026-03103-0
SN  - 0887-6924
SN  - 1476-5551
ER  -